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Summary Slide (4-5 bullet points): 
 Why carry out this study? 
o Accurate assessment of estrogen receptor (ER) expression is crucial to identify 
those breast cancer patients who are most likely to benefit from endocrine 
therapy. 
o Current clinical practice utilizes an ER threshold of ≥ 1% staining by 
immunohistochemistry (IHC); however, this threshold may not accurately classify 
patients. Reverse-transcription polymerase chain reaction (RT-PCR) may provide 
a more precise indication of ER status. 
o The aim of this study was to compare ER expression measured by IHC and the 
21-gene Oncotype DX Breast Recurrence Score® assay, a multigene assay that 
employs RT-PCR-based methodology that has been clinically validated to 
determine the benefit of chemotherapy in patients with ER-positive (ER+) early 
stage breast cancer when treated with endocrine therapy. 
 What was learned from the study? 
o There was a 100% agreement between samples labelled as ER+ (> 10% staining) 
by IHC and by RT-PCR; however, slightly more than half (56%) of samples 
classified as ER-low+ by IHC (1–10% staining) were classified as ER-negative by 
RT-PCR.  
o In patients with low ER expression by IHC, the 21-gene assay provides more 
precise information than IHC in patients with ER-low+ expression (1–10%), 
which can be used to determine which patients are likely to benefit from 
endocrine therapy.  
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ABSTRACT 
Introduction: Accurate assessment of estrogen receptor (ER) expression is crucial to ensure that 
patients with early breast cancer are accurately identified for appropriate treatment with 
endocrine therapy. Reverse-transcription polymerase chain reaction (RT-PCR), compared with 
immunohistochemistry (IHC), may provide a more precise indication of ER status. Data were 
pooled and analyzed from two independent, but similarly designed studies that examined ER 
status by IHC and the 21-gene Recurrence Score that employs RT-PCR-based methodology, 
Methods: Tumor tissue from patients with early stage breast cancer where ER status could be 
determined by both IHC and RT-PCR was included. ER status by IHC staining was defined as 
ER-negative (< 1%), ER-low+ (1–10%), or ER+ (> 10%). ER Status by RT-PCR was defined as 
ER-negative (≤ 6.5) or ER+ (> 6.5). Recurrence Score results from the 21-gene assay were 
reported on a continuous scale from 0 to 100. A sub-analysis examined the association between 
ER expression (Allred score 2–7) and response to a 14-day pre-surgery pulse with an aromatase 
inhibitor. A separate sub-analysis examined the association between ER expression and human 
epidermal growth factor receptor 2 (HER2) expression. 
Results: Tumor specimens from 192 patients (aged 25–92 years) were included in the pooled 
analysis. Correlation between IHC- and RT-PCR-measured ER was strong for IHC-defined ER-
negative and ER+ samples (r = 0.646 [95% CI 0.553–0.720]). There was 100% concordance for 
ER+ tumors; however, 56% of the ER-low+ tumors were negative by RT-PCR. Allred score 
correlated better with ER status measured by RT-PCR at pre-treatment (r = 0.83) than at post-
treatment (r = 0.76).  The majority (77%) of ER-negative and ER-low+ tumors were HER2-
negative. 
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Conclusions: RT-PCR provided a more accurate assessment of ER expression in patients with 
ER-low+ tumors and data support dual testing for patients with ER-low+ status to ensure 
appropriate treatment planning as it pertains to endocrine therapy.  
 
Keywords: 21-gene assay; Breast cancer; Endocrine therapy; Estrogen receptor; Gene 
expression; Immunohistochemistry; Pooled analysis; Proliferation; Recurrence Score; Reverse 
transcriptase-polymerase chain reaction. 
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INTRODUCTION 
The estrogen receptor (ER) is a biomarker used to identify breast cancer patients who are most 
likely to benefit from endocrine therapy, such as tamoxifen or aromatase inhibitors (AIs) [1]. 
Current clinical practice guidelines, such as the National Comprehensive Cancer Network and 
the American Society of Clinical Oncology (ASCO), recommend that patients with ER-positive 
(ER+) early stage breast cancer receive at least 5 years of endocrine therapy and potentially up to 
10 years of therapy in appropriate patients [2, 3]. Although time to disease recurrence is 
inversely related to ER expression level [4], even a very low level of ER expression is associated 
with a clinical benefit from endocrine therapy [5]. Furthermore, quantitative ER expression level 
has also been shown to predict distant recurrence and survival in patients treated with endocrine 
therapy [6].  
 
The changing threshold for determining ER+ early stage breast cancer by immunohistochemistry 
(IHC) has presented a challenge to physicians and patients with respect to whether or not patients 
with lower levels of ER expression should be treated with endocrine therapy. Most recently, the 
ASCO/College of American Pathologists (CAP) guidelines have lowered the threshold from > 
10% to > 1% by IHC staining [5]. Current clinical practice utilizes this ER threshold (> 1% 
staining) or Allred score ≥ 3 for determination of endocrine therapy eligibility [5, 7]. As a result, 
approximately 70% of patients are now being classified as ER+ and appropriate for endocrine 
therapy [8]. While these guidelines have improved ER status assessment through the 
standardization of certain pre-analytic variables (i.e. fixation duration; antibody choice), a 1% 
threshold may be too difficult to accurately replicate using IHC techniques to classify patients as 
ER+ or ER-negative. Recent studies have found that the majority of patients with < 10% ER 
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expression by IHC, similar to patients with ER-negative breast cancer, do not benefit from 
endocrine therapy [9–11]. Further, approximately 15–20% of patients have amplification 
(positive) of the human epidermal growth factor receptor 2 (HER2) [12], and are less likely to be 
responsive to endocrine therapy and require additional HER2 targeted therapy with monoclonal 
antibodies or kinase inhibitors for effective treatment [2]. 
 
Prognosis and treatment decisions are based on the level of ER expression, thus underscoring the 
need for an accurate quantitative assessment of ER, particularly in patients with tumors that have 
low levels of expression – in the 1–10% range (ER-low+). In general, women with ER+ tumors 
tend to have higher 5-year survival rates (85%) compared with women with ER-negative tumors 
(69%) [13]. Additionally, 5–10-year survival rates for women with ER+ early stage breast cancer 
are higher compared to ER-negative tumors across age groups [14]. ER-negative tumors tend to 
have a worse prognosis compared to ER+ tumors, are not responsive to endocrine therapies, and 
require a more aggressive approach usually with upfront chemotherapy [15]. It is estimated that 
approximately 75% of ER-low+ tumors are genetically similar to ER-negative tumors, and 
therefore unlikely to respond to endocrine therapy [16]. Thus, having greater precision of ER 
expression is critical to making the appropriate treatment plan for patients with low ER-
expressing tumors by IHC. 
 
Reverse-transcription polymerase chain reaction (RT-PCR) may provide a more precise 
indication of ER status. Classification of ER status by RT-PCR has been shown to have a >90% 
concordance with IHC [17–19]. Furthermore, in the National Surgical Adjuvant Breast and 
Bowel Project B-14 trial of patients with ER+ early stage breast cancer, ER measured by 
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quantitative RT-PCR was shown to be predictive of benefit from treatment with tamoxifen 
(interaction p < 0.001) [20]. To date, this is the only study that has shown a correlation between 
level of ER expression and response to endocrine therapy. 
 
The 21-gene assay (Oncotype DX Breast Recurrence Score® assay, Genomic Health Inc., 
Redwood City, CA) is a multigene assay that employs quantitative RT-PCR-based methodology 
to generate a Recurrence Score result from RNA extracted from patient tumor tissue samples. 
The assay measures the expression levels of 21 genes, which is then used to calculate the 
Recurrence Score, measured on a continuous scale from 1 to 100 [21]. The 21-gene assay has 
been clinically validated to predict the 10-year risk of distant recurrence and the likelihood of 
benefit from chemotherapy in patients with ER+ early stage breast cancer who are treated with 
endocrine therapy [21–24]. The 21-gene assay also reports quantitative single gene scores for ER 
and progesterone receptor (PR), providing further insight into a patient’s breast tumor biology 
and thus their likelihood of response to endocrine therapy. 
 
IHC methods may be too sensitive at lower expression levels and result in misclassification of 
some patients as having ER+ early stage breast cancer. The aim of the current study was to 
compare ER expression measured by IHC and by RT-PCR (via the 21-gene assay) and compare 
the association between ER levels and endocrine therapy effect in patients with early stage breast 
cancer and ER-negative (< 1%) or ER-low+ (1–10%) expression by IHC.  
 
METHODS 
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Two independent, but similarly designed, studies examined ER status determined by IHC and 
RT-PCR: Study 1 was a prospectively designed exploratory study of archived formalin fixed 
paraffin embedded tumor specimens from a consecutively accrued cohort of 140 patients with 
ER-negative (IHC < 1%) or low+ (IHC 1–10%) early stage breast cancer from New York 
University (see Text S1 and Table S1a in the electronic supplementary material) [25]. ER 
protein was assessed by standard IHC methods using the CONFIRM anti-ER (SP1) antibody 
(Ventana Medical Systems®, Tucson, AZ). HER2 protein assessment used standard IHC 
methods with the anti-HER2/neu (4B5) antibody (Ventana Medical Systems®, Tucson, AZ) with 
reflex testing of HER2 2+ cases by fluorescence in situ hybridization (FISH) (positive defined as 
ratio ≥ 2.0) using the FDA-approved HER2 DNA Probe Kit, Vysis FISH chromosome search 
(Abbott Molecular, Abbott Park, Illinois). FISH Hybridization results were recorded and 
analyzed by BioView Duet system (Allegro Plus Automated Scanner) with HER2 application 
software (BV-HER2-AF). Quantitative HER2 levels were obtained from the RT-PCR assay (via 
the 21-gene assay) as previously described [21, 26]. Study 2 included 55 postmenopausal women 
with low ER-expressing early breast cancer (Allred scores 2–7), who were treated as part of a 
prospectively randomized trial with 2 weeks of endocrine therapy with letrozole or anastozole, 
followed by wide excision, at the Edinburgh Breast Unit (see Text S2 and Table S1b in the 
electronic supplementary material) [27]. Since the data across these two studies included ER 
quantification by IHC and RT-PCR in primary tumor tissue samples of patients with early stage 
breast cancer, we pooled the two datasets to increase the power of the analysis. All ER (by IHC 
and RT-PCR) and HER2 (by RT-PCR) results were assessed per ASCO/CAP guidelines that 
control for pre-analytic, analytic, and post-analytic variables [5, 28]. 
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Pooled Analysis: ER Quantification (IHC vs. RT-PCR)  
Tumor tissue from patients with early stage breast cancer where ER status could be determined 
by both IHC assay and RT-PCR were included in the analyses. Samples were excluded if the 
tumor tissue was not a primary tumor or if insufficient tissue was available for RT-PCR or IHC 
assay analysis. Specimens from patients with early stage breast cancer who were identified as 
ER-negative or ER-low+ by IHC were included in the analysis. ER status by IHC staining was 
defined as: < 1% (ER-negative), 1–10% (ER-low+), or > 10% (ER+). ER Status by RT-PCR was 
defined as ≤ 6.5 (ER-negative) or > 6.5 (ER+). The 21-gene assay was run in the Clinical 
Laboratory Improvement Amendments certified/CAP accredited laboratory at Genomic Health, 
as per standard procedures. Recurrence Score results were reported on a continuous scale from 0 
to 100, with risk classified as low (< 18), intermediate (18–30), or high (≥ 31) [21]. 
 
Association Between ER Level and Prediction of Endocrine Therapy Effect in Patients with 
ER-low+ Status (by IHC) 
A subgroup analysis in postmenopausal women with Allred score 2–7 from Study 2 examined 
the association between ER expression and response to a 14-day pulse pre-surgery with an AI 
(letrozole or anastrozole), followed by wide excision. Pre-treatment Allred score (as determined 
by IHC analysis) and pre- and post-treatment 21-gene assay results were obtained for each 
sample. For all analyses, specimens were grouped into Allred score 2–4 (ER-low+) or Allred 
score 5–7 (ER+). Proliferation was measured by either Ki67 expression, a protein strongly 
associated with cell proliferation [29], using IHC methods or the 21-gene assay based 
proliferation gene group score (PGS). Proliferation response was defined as a ≥ 20% relative 
decrease in Ki67 expression, which was compared against any decrease in PGS [27].  
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Statistical Considerations 
ER expression by RT-PCR and IHC was described and the concordance between ER 
classification by IHC and RT-PCR was calculated. Spearman’s rank correlation coefficient and 
95% confidence intervals [CIs] were calculated for ER expression by RT-PCR and ER percent 
by IHC, and for Recurrence Score result and ER expression by both RT-PCR and ER percent by 
IHC. Distribution of ER by both RT-PCR and by IHC were described among low, intermediate, 
and high Recurrence Score risk groups. 
 
Study 2 analyzed changes in ER status and Ki67 expression, which were assessed using a paired 
t-test; statistical significance was set as p < 0.05 [27]. Correlations and 95% CIs for pre- and 
post-treatment measurements were calculated using Spearman rank statistics. Univariable 
logistic regression was used to test predictors for significant changes in Ki67 by IHC using the 
following co-variates: age; tumor size; Allred score (5–7 vs. 2–4); Recurrence Score; ER 
expression by RT-PCR; ER status by RT-PCR (positive vs. negative); PR expression by RT-
PCR; PGS; Ki67 expression by RT-PCR; and HER2 expression by RT-PCR. Generalized linear 
models were used to test predictors for change in the proliferation axis score. All analyses were 
conducted using SAS v9.3 (SAS Institute, Cary, NC). 
 
Association of HER2 and ER Expression in Patients with ER-Negative or ER-low+  
A sub-analysis from Study 1 examined the association between low/negative ER expression and 
HER2 expression. HER2 status was established via ASCO/CAP guidelines [30].  Reference-
normalized expression measurements ranged from 2 to 15, where each 1-unit increase reflects 
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about a two-fold increase in RNA and HER2 expression. Categories were based on pre-specified 
reference-normalized values (positive ≥ 11.5, equivocal ≥ 10.7 to < 11.5, negative < 10.7). 
All analyses were descriptive in nature and included the distribution of HER2 expression by RT-
PCR and the distribution of the Recurrence Score result across HER2 status by IHC/FISH. HER2 
categorization by IHC/FISH and RT-PCR were compared and positive agreement between 
methods were calculated, which included equivocal results. 
 
This article does not contain any new studies with human or animal subjects performed by any of 
the authors. 
 
RESULTS 
Pooled Analysis: Comparison of ER Status by IHC and RT-PCR 
Overall, tumor specimens from 192 patients (median age 59 [range 25–92] years) were included 
in the pooled analysis (Table 1). The majority of tumors were grade 3 and had high (≥ 31) 
Recurrence Score results (86%).  
 
Overall, the majority of samples (69%; 133/192) were ER-negative (< 1%) by IHC with 20% 
(39/192) classified as ER-low+ (1–10%) and 10% (20/192) as ER+ (> 10%) (see Table 1). In 
Study 1, 76% (106/140) of samples were ER-negative, 24% (34/140) were ER-low+, and 0% 
(0/140) were ER+. In Study 2, 52% (27/52) of samples were ER-negative, 10% (5/52) were ER-
low+ (Allred score 2–4), and 38% (20/52) were ER+ (Allred score 5–7). There was a distribution 
of ER expression measured by RT-PCR, within the IHC defined groups of ER-negative, ER-
low+, or ER+ (Fig. 1). The correlation between IHC- and RT-PCR-measured ER (Fig. 2a–d) 
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was strong for IHC defined ER-negative and ER+ samples (r = 0.646 [95% CI 0.553–0.720]) 
(Fig. 2a). There was a 92% concordance between RT-PCR and IHC in classifying ER-negative 
status samples (Fig. 2b), but only a 63% concordance in classifying samples as ER+. When 
stratified by ER-low+ (1–10% IHC staining; Fig. 2c) or strong ER+ (> 10% IHC staining; Fig. 
2d), the concordance was 100% for tumors that were ER > 10%, but only 44% (17/39) of ER-
low+ tumors were positive by RT-PCR.  Conversely, more than half (56%) of the ER-low+ (1–
10%) tumors were negative by RT-PCR (≤ 6.5). 
 
There was a range of Recurrence Score values across levels of ER expression by IHC (Fig. 3) 
and RT-PCR (see Fig. S1 in the electronic supplementary material) with the majority of 
samples having high Recurrence Score results. Virtually all of the ER-negative samples by both 
IHC and RT-PCR had high Recurrence Score results (Fig. 1). None of the samples that were ER-
negative by either method, or ER-low+ had a low Recurrence Score result (Fig. 2b–c and Fig. 3 
and 4). Of the patient samples with high Recurrence Score results, 79% (by IHC) and 86% (by 
RT-PCT) were ER-negative, 19% (by IHC) were ER-low+, and 2% (by IHC) and 14% (by RT-
PCR) were ER+. There were 3/133 (2%) intermediate scores in the IHC ER-low+ tumors and 
2/144 (2%) intermediate scores in tumors negative by RT-PCR (≤ 6.5). The Recurrence Score 
result correlated more closely to ER expression by RT-PCR compared with ER expression by 
IHC (r = -0.54; 95% CI -0.63 to -0.43 and r = -0.38; 95% CI -0.50 to -0.25, respectively) (see 
Fig. S2a–b in the electronic supplementary material). ER expression tended to be higher in 
patients with a low Recurrence Score result and lower in patients with a high Recurrence Score 
result, regardless of method (Fig. 4a–b). However, within each Recurrence Score result-defined 
risk group (low, intermediate, high) there was a range of ER expression values. 
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Response to 14-day Pulse of an AI: ER Expression, Recurrence Score Result, Proliferation, 
and Ki67 
A sub-analysis examined the effect on ER expression (by RT-PCR), Ki67 expression (relative 
and absolute), and the PGS from the 21-gene assay in 55 patients with Allred score 2–7 who had 
received 14 days of preoperative AI treatment. At pre-treatment, 45% of patients were Allred 
score 2–4 and 55% were Allred score 5–7. ER expression by RT-PCR correlated strongly with 
Allred score (r = 0.83; 95% CI 0.73–0.90) at pre-treatment, and declined, though remained 
strongly correlated, at post-treatment (r = 0.76; 95% CI 0.61–0.85). Pre- and post-treatment ER 
expression by RT-PCR were highly correlated (r = 0.88; 95% CI 0.79–0.93) and there was no 
statistically significant change in the mean (standard deviation [SD]) ER expression following AI 
therapy (6.8 [2.5] vs. 6.7 [2.3], respectively, p = 0.47 [see Fig. S3 in the electronic 
supplementary material]). Similarly, pre- and post-treatment Recurrence Score results were 
also highly correlated (r = 0.93; 95% CI 0.88–0.96), with eight patients (15%) changing risk 
group, three of whom decreased in risk group (two from intermediate to low; one from high to 
intermediate), following AI treatment (see Fig. S4 in the electronic supplementary material). 
 
Pre-treatment Ki67 values were available for 45 (81.8%) samples. Spearman correlations 
between Ki67 by IHC and PGS were moderate in both pre-treatment samples (r = 0.37; 95% CI 
0.08–0.59) and post-treatment samples (r = 0.54; 95% CI 0.28–0.71) (see Fig. S5a–b in the 
electronic supplementary material). There was a significant decrease in mean Ki67 level from 
pre-treatment (18%) to post-treatment (11%; p < 0.001) and the 64% of tumors with no change 
in Ki67 level all had high Recurrence Score results. Pre- and post-treatment PGSs were highly 
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correlated (r = 0.72; 95% CI 0.56–0.83) and there were clear differences between tumors with 
Allred score 2–4 versus Allred score 5–7 (see Fig. S6 in the electronic supplementary 
material). Samples with an Allred score 2–4 showed minimal effect of the AI pulse with a mean 
(SD) change in PGS of 0.07 (0.29), while samples with an Allred score 5–7 showed a mean (SD) 
pre- to post-treatment change in PGS of -0.67 (0.71) (see Fig. S7 in the electronic 
supplementary material). 
 
Of the 45 samples with a pre-treatment Ki67 value available, 28 (62%) had a decrease in both 
Ki67 and PGS after AI treatment. Compared with changes in Ki67 expression, PGS changes 
were more strongly correlated with Recurrence Score result (Fig. 5a-b). Samples in the Allred 
score 5–7 group had the greatest absolute change in PGS (see Fig S7 in the electronic 
supplementary material). Most (88.9%) tumors had an absolute decrease in Ki67 by IHC 
following AI treatment (see Fig S8a in the electronic supplementary material). Pretreatment 
PGS did not predict the change in Ki67 on an absolute or relative scale (see Fig S8b in the 
electronic supplementary material). There was greater relative reduction in both Ki67 
expression and PGS in Allred score 5–7 (73% and 11%, respectively) than Allred score 2–4 
(28% and -1%, respectively) tumors (see Fig. S9 in the supplementary material). By univariate 
logistic regression analysis, Allred score 5–7, Recurrence Score result, ER by RT-PCR, ER+ 
status by RT-PCR, and PR by RT-PCR were all statistically significant predictors of change in 
Ki67 expression (p < 0.01 for each) and PGS (p < 0.0001 for each) (Table 2). Age, tumor size, 
PGS, Ki67 by RT-PCR, and HER2 by RT-PCR were not significant indicators of proliferation 
change (p > 0.05 for each).  
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HER2 Association with ER Expression in Patients with ER-Negative or ER-low+ Status (by 
IHC) 
A third sub-analysis examined the association between HER2 expression in patients with ER-
low+ or negative tumors. HER2 status was determined from tissue samples from 140 patients 
who were ER-negative (76%) or low ER+ (24%) from Study 1 (see Table S2 in the electronic 
supplementary material).  The percent positive agreement between HER2 as measured by RT-
PCR and IHC/FISH was 78% when equivocal cases by RT-PCR were included in the calculation 
(82% when equivocal values were excluded). There was a high level of agreement between 
HER2 IHC methods and RT-PCR for ER-negative samples. The majority (75%) of ER-negative 
and ER-low+ tumors were HER2-negative by RT-PCR (see Table S3 in the electronic 
supplementary material).  
 
DISCUSSION 
In this report, we have examined the correlation between IHC and RT-PCR methods of ER 
assessment in a predominantly lower ER population as defined by using IHC for ER protein 
expression (< 1%, 1–10% and > 10%). We also explored the correlation between these low ER 
expressing carcinomas and the Recurrence Score result, described the effect of a 14-day 
neoadjuvant pulse of an AI on ER expression assessed by both RT-PCR and IHC, and examined 
associations with Ki67 expression by IHC, the PGS by RT-PCR and the Recurrence Score result. 
ER expression by RT-PCR showed a high correlation with ER expression in samples that were 
either ER-negative or ER+ (≥ 10% staining) by IHC (see Table 1). One-hundred percent of 
samples classified as ER+ (> 10%) by IHC methods were ER+ by RT-PCR. However, the 
clinically relevant finding was that in more than half (56%) of samples classified as ER-low+ by 
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IHC (1–10% staining) assessment by RT-PCR showed them to be ER-negative. These findings 
are consistent with those of Iwamato et al. [16], which showed that 76% of ER-low+ samples by 
IHC were negative by mRNA-based methods and had gene signatures consistent with ER-
negative samples. This finding suggests that patients with low ER expression by IHC ER-low+ 
status may derive little or no benefit from the addition of endocrine therapy.    
 
The threshold for defining ER+ status and eligibility for endocrine therapy has been shifting over 
the past decade. Previously an IHC staining level of ≥ 30% was the threshold, which then 
decreased to ≥ 10%, and most recently guidelines from ASCO and CAP now recommend that 
ER positivity should be considered above a 1% threshold [5]. Approximately 6% of tumors have 
low+ or borderline ER status (1–10% ER staining by IHC) [16, 31] and our results suggest that 
IHC may be less accurate in determining true ER expression levels in these low+ tumors with 
contemporary IHC techniques, which presents a greater challenge to physicians and patients 
when making decisions regarding appropriate treatment [16].  However, accurate assessment of 
ER expression is critically important to ensure that patients with early stage breast cancer are 
treated appropriately. ER is both an important predictive and prognostic biomarker. Higher ER 
expression is reflective of the likelihood of responding to endocrine therapy, and patients with 
lower quantitative ER expression treated with endocrine therapy have higher recurrence rates 
compared with patients with higher ER expression [4, 9, 13, 16]. Consequently, accurate 
identification of ER expression is paramount for determining which patients are likely to benefit 
from endocrine therapy and which patients have insufficient levels of ER expression to derive 
any benefit from endocrine therapy and will suffer from avoidable side effects, as well as 
needing a more aggressive approach to their treatment.  Our results show that RT-PCR provides 
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a quantitative, objective and precise assessment of ER expression in patients with ER-low+ 
tumors.  
 
The 21-gene assay has been incorporated into clinical practice for over a decade. The 21-gene 
assay assigns a Recurrence Score result along a continuum from 0–100 to aid clinicians in 
determining whether chemotherapy is necessary in patients with ER+ early stage breast cancer. 
The prospective phase 3 Assigning Individualized Options for Treatment (TAILORx) trial, 
demonstrated that women with ER+, node-negative breast cancer and low Recurrence Scores (0–
10) (n = 1619), who were treated with endocrine therapy alone, had a 9-year freedom from 
recurrence rate of 95.0% and an overall survival rate of 93.7% [32]. Further, endocrine therapy 
alone was non-inferior to chemotherapy in 6711 patients who had an intermediate Recurrence 
Score (11–25).  In our study ER expression was highly correlated with the Recurrence Score 
results. Response to a 2-week pulse of an AI was determined by changes in Recurrence Score 
result, and proliferation (measured by the PGS by RT-PCR or Ki67 by IHC). The Recurrence 
Score result was a strong indicator of which patients had a proliferation response, with a decrease 
in PGS in low and intermediate scores, but not in patients with a high Recurrence Score result. 
Ki67 protein level decreased after the AI pulse, but there was greater variability in the relative 
decrease within the low and intermediate Recurrence Score groups, likely due to the greater 
variability and difficulty in quantitating Ki67 by IHC [33, 34]. Changes in PGS (measured using 
the 21-gene assay) were also seen after a pulse of AIs, showing that changes in PGS could be 
used to assess short-term endocrine sensitivity.  Our AI Pulse substudy also showed that among 
the 55 patients included, the vast majority (92%) of ER-low+ (Allred score 2-4) tissue samples 
were ER-negative by RT-PCR. In contrast, 90% of samples with Allred score 5–7 were ER+. 
20 
 
Allred score correlated better with ER expression measured by RT-PCR at pre-treatment (r = 
0.83) than at post-treatment (r = 0.76).  Finally, 23% of patients with ER-low+ or ER-negative 
tumors by IHC were HER2+ by RT-PCR showing a high level of agreement in between RT-PCR 
and IHC/FISH measurements. 
 
The strengths of this study include participation by several leading academic centers for high 
quality performance and interpretation of the IHC and for using a high-quality central laboratory 
with standardized methods for RT-PCR and performance of the 21-gene assay consistent with 
the TAILORx experience. Additionally, the results support other reports that RT-PCR can 
separate patients into ER+ and ER-negative status in ER-low+ tumors (1–10% by IHC) [9]. The 
analysis of the two datasets suggests that dual testing with IHC and RT-PCR for breast cancers 
with low ER expression may be useful for accurate ER assessment to facilitate therapeutic 
decisions. A similar algorithm is routinely utilized for HER2 assessment for cases with equivocal 
results (IHC/FISH). Finally, this study, showing decreases in Ki-67 IHC expression following a 
brief course of neoadjuvant endocrine therapy without chemotherapy, is supportive of previous 
data showing that the Recurrence Score result is associated with clinical response to neoadjuvant 
letrozole in postmenopausal patients with ER+, HER2-negative, clinically node-negative breast 
cancer [20, 35–37] 
 
Limitations include that the samples were not from randomized clinical trials, the analyses were 
descriptive and correlative and there were not any clinical outcomes, although they do reinforce 
earlier reports that ER measured by RT-PCR and IHC are concordant in clearly ER+ (> 10%)- 
and ER-negative tumors [17, 38].  
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In summary, the value of the Recurrence Score assay result includes identifying many low risk 
patients who will not benefit from the addition of chemotherapy and precise and reproducible 
estimates of quantitative ER gene expression, in addition to the RS, may help guide neoadjuvant 
endocrine treatment decision making. These data support that single gene ER expression from 
the 21-gene assay can more precisely stratify IHC ER-low+ (1–10%) tumors into ER positive 
and negative groups in order to aid physicians and patients in optimal treatment planning. 
 
CONCLUSION 
Accurate measurement of ER is essential for optimal treatment of patients with early stage breast 
cancer. In patiets with ER-low+ tumors by IHC, additional testing may be valuable to assess ER 
status more accurately. Based on the results of this pooled analysis from two independent 
studies, a 1% threshold by IHC to determine ER+ status, as recommend by current treatment 
guidelines, appears to be too low. The current study and a review of previous reports suggest a 
threshold for determining ER+ status by IHC methods should be 10% [9, 11]. The current pooled 
analysis supports the value of measuring ER by RT-PCR in patients with ER-low+ status to 
ensure optimal treatment planning of endocrine therapy, particularly in patients that are HER2-
negative. In patients with lower ER by IHC, the 21-gene assay provides not only more precise 
information than IHC in patients with ER-low+ expression (1–10%) and can be used to 
determine which patients are likely to benefit from endocrine therapy, but also predicts their 
outcome and the need for alternative treatments such as chemotherapy.  
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Figure Legends 
Fig. 1 Estrogen receptor status by IHCa and RT-PCR in 192 patients with early stage breast 
cancer  
aER-low-positive = Allred score 2–4; ER+ = Allred score 5–7 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction 
 
Fig. 2 Correlation of ER expression, measured by IHC and RT-PCR; overall (a), ER-negative (< 
1% IHC staining) (b), ER low+ (1–10% IHC staining) (c), and ER+ (> 10% IHC staining) (d)          
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse transcriptase polymerase 
chain reaction 
 
Fig. 3 Recurrence Score risk group, by IHC ER status (negative or positive) group 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction  
 
Fig. 4 Distribution of ER expression by Recurrence Score risk group, by IHC and RT-PCR; IHC 
(a) and RT-PCR (b) 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction 
 
Fig. 5 Changes in PGS and Ki67 expression, by pre- and post-treatment with AI, and Recurrence 
Score result; PGS (n=45)a (a) and Ki67 (n=45)a (b)  
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 aThe treatment effect is demonstrated by divergence from 0 
AI aromatase inhibitor, PGS proliferation gene group score 
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Tables 
Table 1 Baseline patient demographics and disease characteristics 
Characteristic N = 192 
Median age, years (range) 59 (25–92) 
Mean tumor size, mm (SD) 19.3 (12.4) 
Tumor grade, n (%)  
Grade 1 8 (4) 
Grade 2 43 (22) 
Grade 3 141 (73) 
Tumor subtype, n (%)  
Ductal carcinoma, not otherwise 
specified 
171 (89) 
Lobular 9 (5) 
Mixed/Other   11 (6) 
Missing 1 (<1) 
ER expression level by IHC, n (%)  
Negative (< 1% staining) 133 (69) 
Low (1–10% staining) 39 (20) 
Positive (> 10% staining) 20 (10) 
Mean ER expression level, % (SD)  
IHC 7.94 (20.39) 
RT-PCR 5.42 (1.98) 
Recurrence Score risk group, n (%)  
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Low 5 (3) 
Intermediate 22 (11) 
High 165 (86) 
Median Recurrence Score (range) 54.74 (9.8–100) 
HER2 status by IHC, n (%) N = 140 
0 36 (26) 
1+ 50 (36) 
2+ 21 (15) 
3+ 32 (23) 
Missing 1 
HER2 status by IHC and FISH, n (%) N = 140 
Negative 99 (71) 
Positive 41 (29) 
HER2 status by RT-PCR, n (%) N = 140 
Negative 105 (75) 
Equivocal 3 (2) 
Positive 32 (23) 
ER estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth 
factor receptor-2, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase chain 
reaction, SD standard deviation 
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Table 2 Univariate logistic regression analysis evaluating predictors of proliferation change after 
2 weeks of aromatase inhibitor therapy (Study 2)  
Variable Proliferation measure (p-value) 
≥ 20% relative change in 
Ki67 expressiona 
Decrease in PGSb 
Allred score 5–7 vs. 2–4 0.0017 < 0.0001 
Recurrence Score result 0.0017 < 0.0001 
ER expression, measured by RT-
PCR 
0.0019 < 0.0001 
ER-positive, by RT-PCR 0.0029 < 0.0001 
PR expression, measured by RT-
PCR 
0.0092 < 0.0001 
HER2 by RT-PCR  0.0793 0.1297 
Ki67 by RT-PCR 0.1689 0.979 
Patient age 0.6165 0.1284 
Tumor size 0.8589 0.7312 
aChi-Square Statistic, bT-test 
ER estrogen receptor, HER2 human epidermal growth factor receptor-2, HER2 PGS proliferation 
gene group score, PR progesterone receptor, RT-PCR reverse-transcriptase polymerase chain 
reaction 
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Fig. 1 Estrogen receptor status by IHCa and RT-PCR in 192 patients with early stage breast 
cancer  
 
aER-low-positive = Allred score 2–4; ER+ = Allred score 5–7 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction 
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Fig. 2 Correlation of ER expression, measured by IHC and RT-PCR; overall (a), ER-negative (< 
1% IHC staining) (b), ER low+ (1–10% IHC staining) (c), and ER+ (> 10% IHC staining) (d)  
 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse transcriptase polymerase 
chain reaction 
  
37 
 
Fig. 3 Recurrence Score risk group, by IHC ER status (negative or positive) group 
 
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction 
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Fig. 4 Distribution of ER expression by Recurrence Score risk group, by IHC and RT-PCR; IHC 
(a) and RT-PCR (b) 
  
ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase 
chain reaction  
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Fig. 5 Changes in PGS and Ki67 expression, by pre- and post-treatment with AI, and Recurrence 
Score result; PGS (n=45)a (a) and Ki67 (n=45)a (b)  
 
 
aThe treatment effect is demonstrated by divergence from 0 
AI aromatase inhibitor, PGS proliferation gene group score 
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SUPPLEMENTARY MATERIAL 
 
Text S1 Protocol for Study 1 (New York University [NYU] study) 
 
Overall Study Design 
This was a prospectively designed exploratory study of archived formalin fixed paraffin 
embedded (FPET) tumor specimens from a consecutively accrued cohort of patients from NYU.  
Starting from the most current materials and proceeding in reverse chronologic order to identify 
eligible cases, approximately 140 case (approximately 100 estrogen receptor (ER)-negative and 
approximately 40 ER-borderline cases were to be identified. The study was observational with 
no impact on patient treatment or outcome. 
 
Patient Risks and Benefits 
There were no patient risks or benefits associated with this study protocol. All tissue specimens 
were de-identified prior to sending to Genomic Health (GHI) for further analysis. Assay results 
were for research purposes only and were not used for patient care or treatment decisions. 
 
Study Objectives 
1. To explore the correlation between ER assessments by central immunohistochemistry 
(IHC) and central reverse-transcription polymerase chain reaction (RT-PCR) in IHC ER-
negative (< 1% positive tumor cells) FPET breast tumors 
2. To explore the correlation between ER assessments by central IHC and central RT-PCR 
in IHC ER-borderline (1–10% positive tumor cells) FPET breast tumors 
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Inclusion Criteria  
 FPET tumor tissue from patients diagnosed with early stage invasive breast cancer (IBC) 
 Eligible for analysis after administrative review  
 Consecutive FPET blocks containing IHC ER-negative (< 1% tumor cells positive) or 
IHC ER-borderline (1–10% tumor cells positive) early stage IBC 
 FPET IBC tumor that was available in the NYU pathology archive starting from most 
current materials and reviewing in reverse chronologic order to identify eligible cases 
 
Exclusion Criteria  
 Not primary breast tumor 
 Insufficient IBC (< 2.0 mm) in specimen as assessed by examination of the hematoxylin 
& eosin (H&E) slide by the GHI designated pathologist 
 No IHC assessment of ER available  
 Failure of pre-specified laboratory metrics 
 
Specimen Handling, Blinding, and Testing 
Once identified, specimens were sent to GHI for 21-gene Oncotype DX Breast Recurrence 
Score® assay (21-gene test; Genomic Health, Redwood City, CA) testing. GHI performed the 
21-gene test while blinded to the NYU patient data. Both teams (NYU and GHI) conducted the 
analyses in parallel and jointly reviewed the results. 
 
Patient and Specimen Identifiers 
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NYU ensured an accurate link between the unique patient identifier (PID) assigned by NYU and 
data collected by NYU for each patient included in the study. The PID for each patient specimen 
was recorded on the Specimen Handling Form that was sent to GHI. The PID was provided to GHI 
without any information that would allow identification of the individual such as name, initials, or 
medical record number.     
 
Specimen Specifications 
All FPET blocks submitted had the patient pathology reports reviewed in order to select the same 
sample used for IHC by the Pathologist at NYU to identify all blocks for the 21-gene assay.   
 
The FPET blocks were provided such that each sample yielded a total of 13 x 5 µm unstained 
slides, from which the last slide was H&E stained to provide a guide slide for manual micro-
dissection, should micro-dissection prove necessary. H&E for each patient was scanned and the 
digital image stored. The H&E was returned after completion of sample processing. In addition 
to being the same sample block used for IHC, patient tissue blocks provided to GHI were the 
most representative, e.g. to contain the largest cross sectional area of invasive breast carcinoma.  
 
All residual RNA, beyond that needed for this study and for quality control or regulatory 
purposes, was retained by GHI. Remaining blocks were sent back to the pathologist. 
 
Sample Preparation by GHI 
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 The GHI designated Pathologist microscopically reviewed the H&E to confirm the 
presence and sufficiency of the IBC tumor; then, the tumor area was highlighted using 
indelible ink on the glass H&E slide when manual micro-dissection was necessary 
 When necessary, the tumor and non-tumor elements were manually micro-dissected. The 
enriched tumor was put into microcentrifuge tube(s) for processing 
 Cases with non-tumor metabolically active tissues, such as proliferative fibrocystic 
change, biopsy cavities, skeletal muscle or skin, were manually micro-dissected 
 All excess materials were retained and banked at GHI for regulatory or assay quality 
control and assurance purposes. All residual RNA, beyond that needed for this study and 
for quality control or regulatory purposes, was retained by GHI. Remaining blocks were 
sent back to the pathologist 
 
Pathology Assessment  
To ensure uniformity and consistency in the acquisition of pathology data relevant to the pre-
specified analyses for this study, the pathology data collection was performed on all specimens 
by an academic surgical pathologist(s) with expertise in breast carcinoma. For this study, GHI 
central pathology assessment was performed.   
 
GHI Assay 
RT-PCR for the 21-gene test was performed according to standard procedures. All laboratory 
analyses were performed by designated laboratory personnel blinded to specimen information, 
without knowledge of treatment assignment or clinical outcomes. Expression levels of 21 genes 
used in the calculation of the Recurrence Score were measured as continuous values from the 
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quantitative RT-PCR assay. Gene expression values were normalized relative to the mean of the 
5 reference genes according to pre-specified procedures. Reference-normalized expression 
measurements typically range from 2 to 15, where a 1-unit increase reflects an approximate 2-
fold increase in RNA expression. The Recurrence Score, calculated from the reference-
normalized expression measurements, was reported for each evaluable sample on a scale from 0 
to 100. 
 
Pathology Requirements 
The specimen must have had all of the following characteristics (as assessed by the GHI 
pathologist) to be processed: 
a. IBC must be present  
b. The percentage of invasive carcinoma cells must be ≥ 5% or > 2.0 mm in greatest 
dimension  
c. IHC results for ER 
And one of the following: 
a. The specimen must be ≥ 50% tumor  
OR 
b. The specimen must be < 50% tumor and is amenable to dissection 
 
Pathology Data Variables 
 Pathology variables acquired from NYU Pathology database: 
o Histologic grade using revised Nottingham criteria 
o Histologic subtype  
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o Tumor size (mm) 
 H&E stained tissue sections examined by a GHI pathologist or pathology designee to 
collect standard commercial metrics    
 
Laboratory Data Variables 
 Gene Expression: Reference-normalized expression levels of 16 cancer-related genes 
used in the calculation of the Recurrence Score were reported as values from the GHI 
assay. For each cancer-related gene, cycle threshold (CT) measurements were obtained by 
RT-PCR, and then normalized relative to a set of 5 reference genes according to standard 
procedure  
 Gene Panel: The 21 pre-specified gene expression panel consists of 16 cancer-related 
genes (BAG1, Bcl2, CCNB1, CD68, CEGP1, CTSL2, EstR1, GRB7, GSTM1, HER2, 
Ki-67, MYBL2, PR, STK15, STMY3, SURV), used in the calculation of the Recurrence 
Score, and 5 reference genes (B-actin, GAPDH, GUS, RPLPO, TFRC), used to normalize 
gene expression 
 
The positive/negative cutpoints on the reference-normalized CT scale for ER, progesterone 
receptor (PR) and HER2 are shown in the table below (hormone receptor [HR]+ is defined as 
ER+ and/or PR+; HR-negative is defined as both ER-negative and PR-negative): 
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 Recurrence Score: The Recurrence Score on a scale from 0 to 100 was 
derived from the reference-normalized gene expression measurements. The 
Recurrence Score groups were defined as low (< 18), intermediate (18–30) 
and high (≥ 31) 
 
Clinical Data Variables 
Data collection was conducted under the direction of the primary investigator. In addition to the 
variables noted above, patient demographics and clinical data may have included the following: 
1. ER status by IHC (intensity and percentage positive cells if applicable) 
2. PR status by IHC (intensity and percentage positive cells if applicable) 
3. HER2 status by IHC (intensity and percentage positive cells if applicable) 
4. Patient age 
 
Additional Data Handling 
Hormone receptor status genes and cutpoints (measured in reference-normalized CT values) 
Gene HR 
Negative Equivocal Positive 
ER < 6.5 N/A ≥ 6.5 
PR < 5.5 N/A ≥ 5.5 
HER2 < 10.7 10.7 to < 11.5 ≥ 11.5 
47 
 
No GHI personnel had access to the un-blinded Clinical Data until after the GHI data were 
locked. Upon lock of GHI data, NYU transferred their data to GHI using GHI’s secure web 
portal. Upon receipt of the NYU data, GHI merged the NYU data and the GHI data and both 
teams were able to conduct the analyses in parallel and jointly review obtained results.  
 
Statistical Methods 
GHI performed the 21-gene test while blinded to the NYU patient data. Both teams (NYU and 
GHI) were able to conduct the analyses in parallel and jointly review obtained results. Pre-
specified assay metrics, as defined in the associated laboratory protocol, were used to identify the 
evaluable assay results. The distribution of ER single gene scores were characterized using 
descriptive statistics separately for the patients who were ER+ by IHC and those who were 
borderline ER+ by IHC. The proportion of evaluable patients who were ER+ by RT-PCR were 
calculated, along with the 95% confidence interval (CI) for the patients who were ER+ by IHC 
and those who were borderline ER+ by IHC.   
 
Sample Size and Power 
If 85% of 140 patients were ER+ by RT-PCR, the 95% CI for the proportion would be (70.2%, 
94.3%). If 80% of 140 patients were ER+ by RT-PCR, the 95% CI for the proportion would be 
(64.4%, 90.9%).  
 
Study Document Access and Availability, and Record Keeping 
The primary investigator ensured the reliability and accuracy of the data provided to GHI, 
maintaining the confidentiality of the documents and tissue samples. The 
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Investigator(s)/Institution(s) permitted research-related monitoring audits, institutional review 
board (IRB)/EC review, and regulatory inspections by providing direct access to service 
data/documents. The investigator ensured the reliability and availability of the source. The 
primary investigator was responsible for maintaining adequate records to enable the conduct of 
the study to be fully documented. 
 
Confidentiality and Ethical Issues 
All tumor samples and reports were submitted to GHI without any information that would allow 
identification of the individual (i.e., name, social security number, and any number assigned by 
the hospital or medical office). Patient identification information were blocked out by the 
investigator prior to shipping to GHI. Reports and tissues were labeled with a serial number 
assigned by the primary investigator or designee, which enabled at the conclusion of the study 
linking assay data back to clinical data. The primary investigator was responsible for conducting 
this research protocol. The study was reviewed and approved by an Institutional Review 
Board/Ethics Committee and appropriate Scientific Review Committees prior to initiation, as 
required.   
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Text S2 Protocol for Study 2 (Edinburgh Breast Unit study) 
 
Overall Study Design 
This was a prospectively designed study in postmenopausal women with low estrogen receptor 
(ER)-expressing early breast cancers who were treated with an aromatase inhibitor (letrozole or 
anastrozole) for 2 weeks to determine if aromatase inhibitors reduced proliferation in low-ER-
expressing cancers. 
 
Study Aims 
1. To correlate estrogen receptor (ER) levels by Allred score (immunohistochemistry [IHC]) vs. 
reverse transcriptase polymerase chain reaction (21-gene assay)  
2. To describe changes in ER, the Recurrence Score result, and measures of proliferation after 2 
weeks of treatment with an aromatase inhibitor 
3. To perform exploratory analyses of factors associated with changes in proliferation  
 
Patient Population 
 Post-menopausal women with early breast cancer and lower ER (Allred score 2–7) 
 
Treatment 
 Two weeks of an aromatase inhibitor (letrozole or anastrozole) followed by wide excision 
 
Methodology 
 Only pre-treatment Allred scores were obtained 
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 All patients had a 21-gene assay on a pre-and post-treatment sample 
 Proliferation was measured by Ki67 using IHC (in 45 patients) and by the proliferation 
gene group score (PGS) in the 21-gene assay (in all patients) 
 Proliferation response was defined by a 20% relative decrease in Ki67 or any decrease in 
PGS 
 Changes in proliferation (Ki67 and/or PGS) were correlated with Allred score, ER-PCR, 
and the 21-gene Recurrence Score result 
 
Statistical Methods 
 Correlations for measurements before and after treatment were calculated using 
Spearman rank statistics. For all analyses, patients were grouped by AS 2–4 or 5–7 
 p-values for significant change in ER and Ki67 were obtained using a paired t-test 
 Logistic regression was used to test predictors for significant change in Ki67 
 Generalized linear models were used to test predictors for change in the proliferation axis 
score 
 SAS version 9.3 statistical software was used 
 
Ethics 
Patients were recruited under ethical approval from the South East Scotland Research Ethics 
Committee 03, approved in 2002, reference LREC/2002/8/23.  
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SUPPLEMENTARY TABLES AND FIGURES 
Table S1 Demographics and baseline characteristics of patients in Study 1 (A) and Study 2 (B) 
A. Study 1 (New York University) 
Characteristic n 
 (N = 140) 
ER status, by IHC, n (%) 
Negative 
(n = 106) 
Borderline 
(n = 34) 
Age, years    
< 50 43 32 (30.2) 11 (32.4) 
50–59 36 28 (26.4) 8 (23.5) 
60–69 30 25 (23.6) 5 (14.7) 
≥ 70 31 21 (19.8) 10 (29.4) 
Histologic grade    
Well differentiated 2 0 (0.0) 2 (5.9) 
Moderately differentiated 21 11 (10.4) 10 (29.4) 
Poorly differentiated 117 95 (89.6) 22 (64.7) 
Positive nodes    
0 86 71 (75.5) 15 (48.4) 
1–3 32 18 (19.1) 14 (45.2) 
> 3 7 5 (5.3) 2 (6.5) 
Tumor size, cm    
< 2 92 71 (67.0) 21 (61.8) 
2 to < 4 41 28 (26.4) 13 (38.2) 
> 4 7 7 (6.6) 0 (0.0) 
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PR status, by IHC    
Negative 116 96 (90.6) 20 (58.8) 
Positive 24 10 (9.4) 14 (41.2) 
HER2 status, by IHC    
0 36 28 (26.7) 8 (23.5) 
1+ 50 40 (38.1) 10 (29.4) 
2+ 21 14 (13.3) 7 (20.6) 
3+ 32 23 (21.9) 9 (26.5) 
Missing 1 1 0 
HER2-positive    
Yes 34 24 (22.6) 10 (29.4) 
No (IHC 3+ or FISH > 2.2) 106 82 (77.3) 24 (70.5) 
 
 
B. Study 2 (Edinburgh Breast Unit) 
Characteristic n (%) 
 (N = 55) 
Age, years  
< 50 1 (2) 
50–59 17 (31) 
60–69 19 (35) 
≥ 70 18 (33) 
Histologic grade  
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Well differentiated 7 (13) 
Moderately differentiated 20 (36) 
Poorly differentiated 28 (51) 
Tumor size, cm  
< 1 4 (7) 
1–2 28 (51) 
> 2 21 (38) 
Missing 2 (4) 
Tumor subtype  
Ductal 45 (82) 
Lobular 5 (9%) 
Other 5 (9%) 
ER Allred score at baseline  
2 7 (13) 
3 11 (20) 
4 7 (13) 
5 9 (16) 
6 4 (7) 
7 17 (31) 
ER estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth 
factor receptor-2, IHC immunohistochemistry, PR progesterone receptor 
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Table S2 HER2 status as measured by IHC/FISH and RT-PCR in patients with early stage breast 
cancer and ER-negative (n = 106, 76%) or ER-low+ (n = 34, 24%) expression (Study 1) 
HER2 status 
by  IHC FISH 
HER2 status by RT-PCR, n (%) 
Negative Equivocal  Positive Total 
Negative 98 (99) 1 (1) 0 99 (100) 
Positive 7 (17) 2 (5) 32 (78) 41 (100) 
Total 105 (75) 3 (2) 32 (23) 140 (100) 
 
ER estrogen receptor, FISH fluorescence in situ hybridization, HER2 human epidermal growth 
factor receptor-2, IHC immunohistochemistry, NA not applicable, RT-PCR reverse-transcriptase 
polymerase chain reaction 
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Table S3 HER2 status as measured by RT-PCR in patients with early stage breast cancer and 
negative or ER-low+ expression (Study 1) 
ER status (by IHC) HER2 status (by RT-PCR), n (%) 
Negative Equivocal Positive Total 
Negative  82 (77) 2 (2) 22 (21) 106 (100) 
Low 23 (68) 1 (3) 10 (29) 34 (100) 
Total 105 (75) 3 (2) 32 (23) 140 (100) 
ER estrogen receptor, HER2 human epidermal growth factor receptor-2, IHC 
immunohistochemistry, RT-PCR reverse-transcriptase polymerase chain reaction 
 
 
56 
 
Fig. S1 Recurrence Score result group by RT- PCR ER expression group (negative or positive)  
 
  ER estrogen receptor, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase chain reaction 
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Fig. S2 Scatterplot of Recurrence Score results by continuous ER (IHC or RT-PCR); IHC (a), RT-PCT (b) 
 
ER estrogen receptor, CI confidence interval, IHC immunohistochemistry, RT-PCR reverse-transcriptase polymerase chain reaction 
  
58 
 
Fig. S3 Change in ER expression (RT-PCR) 
 
ER estrogen receptor, RT-PCR reverse-transcriptase polymerase chain reaction 
59 
 
Fig. S4. Changes in Recurrence Score results relative to Ki67 change after AI pulse (IHC) 
 
   AI aromatase inhibitor, CI confidence interval, IHC immunohistochemistry 
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Fig. S5 Comparison of Ki67 vs. PGS pre- (a) and post-treatment (b) with AI 
                                                                                                               
AI, aromatase inhibitor, PGS proliferation gene group score 
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Fig. S6 PGS changes post-treatment with AI 
 
AI aromatase inhibitor, PGS proliferation gene group score 
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Fig. S7 Comparison of change in Ki67 expression versus PGS following 2 weeks of aromatase inhibitor therapy. Tumors with no 
decrease in Ki67 are shown in the purple box, while tumors with no decrease in PGS are shown in the orange box 
 
PGS proliferation gene group score 
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Fig. S8 Change in Ki67 with pre-treatment PGS; change on an absolute scale (a) and change on a relative scale (b) 
 
PGS proliferation gene group score 
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Fig. S9 Relative reductions in Allred score 
 
PGS proliferation gene group score, ER estrogen receptor 
